Figures & data
Table 1 Patients’ characteristics, overall and by country
Table 2 Clinical profile of patients according to type of medication used
Figure 1 Type and frequency of medication used, overall and by country.
Abbreviations: LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
![Figure 1 Type and frequency of medication used, overall and by country.](/cms/asset/e5d0a9b4-a1a4-4464-98fb-766c719c41f5/dcop_a_154097_f0001_b.jpg)
Figure 2 Type of medication used according to the GOLD 2013 stage classification in the overall population.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
![Figure 2 Type of medication used according to the GOLD 2013 stage classification in the overall population.](/cms/asset/9c56dea9-d3ad-42cf-8042-ebd786809bbe/dcop_a_154097_f0002_b.jpg)
Figure 3 Adherence to treatment (TAI questionnaire) according to the type of medication used in the overall population.
Abbreviations: TAI, Test of Adherence to Inhalers; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
![Figure 3 Adherence to treatment (TAI questionnaire) according to the type of medication used in the overall population.](/cms/asset/54409960-50d6-40ab-b7a6-ec2e00890982/dcop_a_154097_f0003_b.jpg)
Figure S1 Pattern of use of respiratory medication, either as-needed or as regular maintenance therapy.
Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.
![Figure S1 Pattern of use of respiratory medication, either as-needed or as regular maintenance therapy.Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.](/cms/asset/27787894-062e-482a-ad08-81bba5415d3e/dcop_a_154097_sf0001_b.jpg)
Figure S2 Type of medication used according to prior medical diagnosis of asthma.
Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.
![Figure S2 Type of medication used according to prior medical diagnosis of asthma.Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.](/cms/asset/a185f970-9dae-4f98-9b05-8a331ca60fa0/dcop_a_154097_sf0002_b.jpg)
Figure S3 History of exacerbations (ambulatory or requiring hospitalization) in the past year.
Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.
![Figure S3 History of exacerbations (ambulatory or requiring hospitalization) in the past year.Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.](/cms/asset/2c241570-6ec0-4ef5-80f6-d65478858bc4/dcop_a_154097_sf0003_b.jpg)
Table S1 Approval committees in the various countries involved in the LASSYC study